The study published on March 11 shows that children with severe E. coli infections receive significantly less protective antibodies before birth.

Monoclonal antibodies are among the most widely used biologic medicines, with applications ranging from cancer treatment to autoimmune disease therapy. However, during manufacturing, storage, or ...

Today, advancements in medicine have rendered HIV a manageable condition that allows most individuals to enjoy a typical lifespan. What it often takes to achieve that level of longevity, however, is ...

While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

Although the Graves disease treatment landscape remains challenging, emerging therapies could shift existing treatment ...

There are two main goals of antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis (AAV) treatment. The first goal is to bring the condition into remission by controlling active ...

Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 ...

Scientists show that lecanemab clears amyloid plaques by engaging microglia through its Fc fragment, defining the cellular program behind its therapeutic effect ...

During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines. Patients with relapsed/refractory ...

Monoclonal antibodies are a type of biologic medication that can treat moderate to severe inflammatory bowel disease (IBD) by targeting specific inflammatory processes in your body. Your doctor might ...

Scientists at Fred Hutch Cancer Center have reported an important advance in the effort to stop Epstein Barr virus (EBV), a virus believed to infect about 95% of people worldwide. EBV has been linked ...

Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, offering prolonged remissions. Approval would mark the first bispecific ...